MedTrace Logo

Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients

NCT01056679 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-03-22

No results posted yet for this study

Summary

The purpose of this study is to determine within the scope of the trial what the maximum tolerated dose (MTD) of lenalidomide in combination with AVD should be.

Conditions

Interventions

DRUG

Doxorubicine

50mg/m2 day 1 + 15

DRUG

DTIC

375mg/m2 day 1 + 15

DRUG

Lenalidomide

day 1 - 21

DRUG

Vinblastine

6mg/m2 day 1 + 15

Sponsors & Collaborators

  • University of Cologne

    lead OTHER

Principal Investigators

  • Andreas Engert, Prof. · University of Cologne

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2014-04-30
Completion
2016-02-29

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01056679 on ClinicalTrials.gov